Brind.

Immunome adheres to Nasdaq Listing Rule 5635(c)(4).

3 reports, 1 independent Updated Sep 5

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Immunome adheres to Nasdaq Listing Rule 5635(c)(4).

Who's involved

What this event is mainly about

Immunome (United States)

Keep exploring

The entities involved

Immunome (United States)
company in Philadelphia, United States
- Immunome is developing targeted cancer therapies; on August 7, 2025, the EMA granted Orphan Drug Designation to varegacestat, and the FDA also granted the designation.Fri 13:16

Coverage

Newest first; wire copies grouped

Sep 5Business WireImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., September 04, 2025--(BUSINESS WIRE)--Immunome, Inc. (the "Company") (Nasdaq: IMNM), a biotechnology company foc
Aug 2Business WireImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., August 01, 2025--(BUSINESS WIRE)--Immunome, Inc. (the "Company") (Nasdaq: IMNM), a biotechnology company focuse
Jul 4Unknown outlet